Phase I Trial of DLL3/CD3 IgG-Like T-Cell Engager Obrixtamig* (BI 764532) in Patients with DLL3-Positive Tumors: Patients with LCNEC-L

Felip, Enriqueta; Fang, Xiaoyan; Bouzaggou, Mohamed; Studeny, Matus; Villaruz, Liza; Wolf, Jürgen; Arriola, Edurne; F Sanmamed, Miguel; Sayehli, Cyrus; Morgensztern, Daniel; B Alese, Olatunji; Kuboki, Yasutoshi; Gambardella, Valentina; Wermke, Martin

doi:10.60915/Boehringer-figshare.27965973.v2

Phase I Trial of DLL3/CD3 IgG-Like T-Cell Engager Obrixtamig* (BI 764532) in Patients with DLL3-Positive Tumors: Patients with LCNEC-L

poster

posted on 2024-12-09, 02:38 authored by Enriqueta Felip, Xiaoyan Fang, Mohamed Bouzaggou, Matus Studeny, Liza Villaruz, Jürgen Wolf, Edurne Arriola, Miguel F Sanmamed, Cyrus Sayehli, Daniel Morgensztern, Olatunji B Alese, Yasutoshi Kuboki, Valentina Gambardella, Martin Wermke

The above is an infographic providing background on a phase I trial of DLL3/CD3 IgG-like T-cell engager Obrixtamig* (BI 764532) in patients with DLL3-positive tumors. Unless otherwise specified, the content for this infographic has undergone a medical, legal, and regulatory (MLR) review and approval process by Boehringer Ingelheim. Content developed with authors.

History

Disclaimer

This study was sponsored by Boehringer Ingelheim. Medical writing support provided by Ashfield MedComms agency and Esher Nandra writer. Medical Writing support and open access APCs were funded by Boehringer Ingelheim.

Phase I Trial of DLL3/CD3 IgG-Like T-Cell Engager Obrixtamig* (BI 764532) in Patients with DLL3-Positive Tumors: Patients with LCNEC-L

History

Disclaimer

Usage metrics

Categories

Keywords

Licence

Exports